Safety Notices

From time to time notices relating to the safety, efficacy and quality of human medicinal products are published by the Health Products Regulatory Authority.

The issues covered by these notices include medicinal product safety information, updated efficacy information on the appropriate usage of medicines and quality defect information.

Notices are categorised in accordance with their importance at time of publication.

The four notice categories are outlined as follows:

  • Advisory  -  Routine safety information            
  • Warning  -  Urgent safety information
  • Recall  -  Urgent safety information relating to a product recall
  • Publications  -  General information provided by 3rd parties as approved by the HPRA, e.g. MIMS, Direct Healthcare Professional Letter or Product Information Update

The HPRA Drug Safety Newsletter is also published on a regular basis.

Date Title Type
24/10/2011 Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board 24.10.2011 3rd Party Publications
14/10/2011 Important changes to prescribing information for Tazocin and Generic Piperacillin/Tazobactam products Advisory
04/10/2011 Revatio (sildenafil citrate) - Important Safety Information from Pfizer Healthcare Ireland as approved by the Irish Medicines Board 3rd Party Publications
04/10/2011 CHMP Pharmacovigilance Working Party Monthly report - September 2011 3rd Party Publications
03/10/2011 Non-Prescription Cough and Cold Medicines for Young Children - New Advice 3rd Party Publications
03/10/2011 Rimcazole Clinical Trial at Shandon Clinic – IMB Report 3rd Party Publications
22/09/2011 Romiplostim (Nplate) - Important Safety information from AMGEN Ireland as approved by the Irish Medicines Board 3rd Party Publications
19/09/2011 Non-prescription cough and cold medicines for young children - New advice issued by the Irish Medicines Board 3rd Party Publications
19/09/2011 New advice for healthcare professionals regarding non-prescription cough and cold medicines for young children Advisory
05/09/2011 Pioglitazone – New contra-indications and warnings following European review of bladder cancer risk 3rd Party Publications